Drugs / fH1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06460064 | Jun 2024 → Mar 2026 | influenza | Sumitomo Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fH1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06460064 ↗ |
| Modality | Vaccine | “adjuvanted Universal Influenza Vaccine (fH1/DSP-0546LP)” NCT06460064 ↗ |